Why LX2006 Gives Lexeo (LXEO) a Clear Regulatory Path—and a Trade Worth Taking
Lexeo Therapeutics's LX2006 has produced consistent interim signals of clinical activity in Friedreich ataxia cardiomyopathy and the company has active regulatory engagement with the FDA around accelerated and registrational pathways. With a sub-$400M market cap, visible milestones and recent balance-sheet reinforcement, LXEO is a high-risk, high-r…